

To.

Date: 13.11.2020

**BSE** Limited P.J. Towers. Dalal Street. Mumbai - 400 001

Metropolitan Stock Exchange of India Limited Vibgyor Towers, 4th floor, Plot No. C62, Opp. Trident Hotel, BandraKurla Complex, Bandra (E), Mumbai- 400 098

Dear Sir/Madam

Sub: Outcome of board meeting under Regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: (Scrip code: 539267/ DRHABEEB)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Dr Habeebullah Life Sciences Limited held on Friday, 13.11.2020 at 3.30 P.M. at the registered office of the Company, the following were considered and approved by the Board:

- 1. Un-Audited financial results (Standalone & Consolidated) for the quarter II and half year ended 30.09.2020.
- 2. Limited Review Report (standalone & consolidated)along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the guarter ended 30.09.2020

The meeting of the Board of Directors commenced at 03:30 P.M.(IST) and concluded at 5.30 P.M (IST).

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully.

For Dr Habeebullah Life Sciences Limited

K.KrishnamRaiu Whole-Time Director

(DIN: 00874650)

Encl: as above

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500048, TS, india. Regd. UII : 2-3-3-7, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008, TS, India-Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008, TS, India-Email: cs@arbisi.com, info@drhisi.com, prproductsinder@gnoileon CIN No.: L85110TG1996PLC099198.

Contact No.: 040 - 2970 3333, +91 9030057370.

Website: www.drhlsl.com

	STANDALONE UNAUDITED FINANCIAL	RESULTS FOR T	HE QUARTER AND	HALF YEAR ENDE	D 30TH SEPTEMBER	2 2020	in Lakhs.)
	Particulars	Quarter ended		Half Year ended		Tu	
S.No		3 Months ended 30-09-2020	Corresponding 3 months ended in previous year 30-09-2019	Preceding 3 months ended 30-06-2020	Half year ended 30-09-2020	Half year ended 30-09-2019	Year ended 3 03-2020
		Unaudited	Unaudited	Unaudited	Unaudited		
ı	Revenue from Operations	-	35.26	1.30	1.30	Unaudited	Audited
II .	Other Income	3.64	5.64	3.54	7.18	77.48	143.1
Ш	Total Revenue (I+II)	3.64	40.90	4.84	8.48	5.64 83.12	15.8
IV	Expenses		30		0.40	83.12	159.0
	Cost of Material Consumed	-	5.90	0.19	0.19	13.15	22.4
	Employee benefits expense	12.72	29.02	12.24	24.96	58.90	125.9
	Depreciation and Amortisation expense	0.27	0.24	0.26	0.53	0.48	1.08
	Other Expenses	21.13	55.15	18.48	39.61	120.27	198.49
	Total Expenses	34.12	90.31	31.17	65.29	192.80	348.02
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(30.48)	(49.41)	(26.33)	(56.81)	(109.68)	
VI	Exceptional Items		-	-	150,02)	(109.08)	(189.01
VII	Profit/(Loss) before tax (V-VI)	(30.48)	(49.41)	(26.33)	(56.81)	(109.68)	(190.01)
VIII	Tax Expense:	-	-	-	(55:52)	(103.00)	(189.01)
	Current Tax	100		-	2		
	Deferred Tax	-		-			
IX	Profit/ (Loss) for the period from Continuing						-
	operations (VII-VIII)	(30.48)	(49.41)	(26.33)	(56.81)	(109.68)	(189.01)
Χ	Profit/ (Loss) from discontinuing operations	-				(203.00)	(105.01)
ΧI	Tax Expense of discontinuing operations				-	•	-
XII	Profit/ (Loss) for the period from discontinuing	-	-	-	* .	-	-
	operations after tax (X-XI)	-	-	-	-	-	
XIII	Profit/ (Loss) for the period (IX+XII)	(30.48)	(49.41)	(26.33)	(56.81)	(109.68)	(189.01)
XIV	Other Comprehensive Income  A) (i) Items that will not be reclassified to profit or loss  (ii) Income Tax related to items that will not be reclassified to profit or loss  B) (i) Items that will be reclassified to profit or loss  (ii) Income Tax relating to items that will be	1.42	_	_	1.42		1.85
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other						1.03
	Comprehensive Income for the Period)	(29.06)	(49.41)	(26.33)	(55.39)	(109.68)	(187.16)
ΚVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)  1) Basic  2) Diluted	(0.20) (0.20)	(0.33) (0.33)	(0.18)	(0.37)	(0.74)	(1.28)
(VII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)  1) Basic 2) Diluted			(0.18)	(0.37)	(0.74)	(1.28)
VIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/-each)	-	-	-	-	-	
	1) Basic	(0.20)	(0.33)	(0.18)	(0.37)	(0.74)	(1.28)
	2) Diluted	(0.20)	(0.33)	(0.18)	(0.37)	(0.74)	(1.28)
IX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1480.87	1,480.87	1,480.87	1480.87	1480.87

Notes:

- The above unaudited standalone financial results for the quarter and half year ended 30 September 2020 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Friday 13 November 2020.
- The unaudited standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- The format for the Standalone Unaudited quarterly and half year results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed.
- The EPS for quarters has not been annualized.
- The company continues to consider the impact of COVID-19 pandemic in assessing the improvement of business and recoverability of receivables. For this purpose, the company considered internal and external sources of information up to the date of approval of these financial results.

  The Company based on its judgements, estimates and assumptions expects to recover the carrying amount of receivables and other assets.

  The impact of the global health pandemic may be different from that estimated as at the date of approval of financials results and the Company will continue to closely monitor any material changes to future economic conditions.

  Entity operated its hospital in the month of June'2020 only for seven days after relaxation of lockdown rules but later the same was shut down and not stared till date. Hence there is no revenue in second quarter i.e. July 2020 September 2020.
- The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- 7 The unaudited financial results for the quarter and half year ended 30 September, 2020 are also available on the website of the Company www.drhlsl.com.
- 8 The Previous quarters/ year's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

Place : Hyderabad Date : 13/11/2020 FOR DR HABEEBULLAH LIFE SCIENCES LIMITED LIFE

K. Krishnam Raju Executive Chairman (DIN 00874650)

		t of Assets and Liabilities	
	Particulars	Half Year Ended 9/30/2020 (Unaudited)	(Amount in Lakh Year Ended 3/31/2020 (Audited)
	ASSETS		
	Non Current Assets		
	Property, Plant and Equipment	2.22	2.7
	Capital Work In Progress	-	-
	Investment Property Goodwill		-
	Other Intangible Assets		-
	Intangible Assets under development	321.45	303.
	Biological assets other than bearer plants	-	505.
	Financial Assets:	-	
	Investments	487.06	487.0
	Trade Receivables	-	-
	Others	204.20	-
	Loans	204.28	204.2
	Others		-
	Deferred Tax Assets (net)		-
	Other Non Current Assets	-	
	Total Non Current Assets	1,015.01	997.3
	c		
	Inventories	12.02	222
	Financial Assets	12.92	13.1
	Investments		-
	Trade Receivables	214.26	217.5
	Cash and Cash Equivalents	0.80	2.3
	Bank balances other than above	-	-
	Loans and Advances	134.00	134.0
	Other financial assets	30.75	24.1
	Other Current Assets	204.55	- 2017
	Total Current Assets	304.55 <b>697.28</b>	304.3 <b>695.4</b>
	Total Assets	1,712.29	1,692.7
	EQUITY AND LIABILITIES		
	Equity		
- 1	Equity Share Capital	1,480.87	1,480.8
- 1	Other Equity	-,	2,400.0
- 1	Share Warrants	-	
- 1	Reserves and Surplus	(293.33)	(237.9
- 1	Non-Controlling Interests	- 1107.51	-
	Total - Equity	1,187.54	1,242.9
- 1	Liabilities		
-	Non Current Liabilities		
- 1	Financial Liabilities Borrowings		
-	Trade Payables		-
	Other Financial Liabilities		-
н	Provisions	14.48	14.5
	Deferred Tax Liabilities (net)	-	
	Other Non Current Liabilities		-
1	Total Non Current Liabilities	14.48	14.5
,	Current Liabilities		
ш	Financial Liabilities		
	Borrowings	211.30	179.1
	Frade Payables	34.93	30.5
	Other Financial Liabilities	-	-
(	Other Current Liabilities	261.20	223.2
	Provisions	2.84	2.4
	Current Tax Liabilities (net)	-	-
7	Total Current Liabilities	510.27	435.2
	otal - Equity and Liabilities	1,712.29	1,692.7

( Kalahaan Balia

K. Krishnam Raju Executive Chairman (DIN 00874650)

Place: Hyderabad Date: 13/11/2020

# DR HABEEBULLAH LIFE SCIENCES LIMITED STANDALONE STATEMENT OF CASH FLOWS

(Amount in Lakhs.)

		(Amount in Lakhs.)			
PARTICULARS	Half Year ended	Half Year ended			
	September 30, 2020	September 30, 2019			
A. CASH FLOW FROM OPERATING ACTIVITIES:					
Net profit before tax	(55.39)	(109.68			
Adjustment for:		(107.00			
Depreciation and Amortisation	0.53	0.48			
Interest Expenses		-			
Interest Earned		(5.64			
Cash Flows from Operations before changes in assets and liabilities	(54.86)	(114.84			
Movements in Working Capital::		(2)			
(Increase)/ Decrease in trade receivables	3.26	0.53			
(Increase)/ Decrease in Short Term Loans and Advances		0.55			
(Increase)/ Decrease in other Current Assets	(0.24)	(74.73			
(Increase)/ Decrease in other other financial Assets	(6.65)	(71.75)			
(Increase)/ Decrease in Inventories	0.19	0.11			
Increase / (Decrease) in Trade Payables	4.43	9.88			
Increase/ (Decrease) in Other current liabilities	38.00	71,91			
Increase/ (Decrease) in Current Provisions	0.40	(0.77)			
Change in Working Capital	39.40	6.93			
Changes in non surrent assets and liabilities					
Changes in non current assets and liabilities					
Decrease/(Increase) in loans & advances (Decrease)/Increase in Long Term Perrowings		(1.73)			
(Decrease) / Increase in Long Term Borrowings	(0.04)				
(Decrease)/Increase in Long Term Provisions	(0.01)	0.76			
Changes in non current assets and liabilities	(0.01)	(0.97)			
Cash Generated From Operations	(15.47)	(108.88)			
Less: Taxes paid	-				
Net Cash from operating activities(A)	(15.47)	(108.88)			
B. CASH FLOW FROM INVESTING ACTIVITIES					
(Increase) / Decrease in Fixed assets and Capital Work In progress	(18.23)	(48.66)			
Bank Balances not considered as Cash and Cash equivalents		(10:00)			
Investment in equity Shares					
Interest received		5.64			
Net cash used in Investing activities (B)	(18.23)	(43.02)			
C.CASH FLOW FROM FINANCING ACTIVITIES					
Increase / (Decrease) in Share Capital		150.00			
Increase / (Decrease) in Borrowings	32.15	2.75			
Interest paid	32.13	2.73			
Net cash Flow from Financing Activities ( C )	32.15	152.75			
		2000000			
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(1.55)	0.85			
Cash & Cash Equivalents At The Beginning Of The Year	2.35	1.50			
Cash & Cash Equivalents At The End Of The Year	0.80	2.35			

For and on behalf of the Board for DR HABEEBULLAH LIFE SCIENCES CHANTED FE S

(K.Krishnam Raju)

Whole-time Director & Chairman

DIN: 00874650

Place: Hyderabad Date: 13/11/2020

PART-I						4.	
	CONSOLIDATED UNAUDITED FINANCIAL R	ESULTS FOR TH	E QUARTER AND H	ALF YEAR ENDED	30TH SEPTEMBER	(Amount in	Lakhs.)
	Particulars		Quarter ended			ar ended	Vannada
	, ardediars	3 Months	Corresponding 3	Preceding 3	Half year ended	Half year ended	Year ende
		ended	months ended in	months ended	30-09-2020	30 00 3040	31-03-202
S.No		30-09-2020	previous year	30-06-2020		30-09-2019	
			30-09-2019				
	l 1	Itsed	Unaudited	Unaudited			
		Unaudited	35.26	1.30	Unaudited	Unaudited	Audited
	Revenue from Operations		5.64		1.30	77.48	143
1	Other Income	3.64	40.90	3.54	7.18	5.64	15.
11	Total Revenue (I+II)	3.64	40.90	4.84	8.48	83.12	159.
V	Expenses		5.00	0.10			
	Cost of Material Consumed	-	5.90	0.19	0.19	13.15	22
	Employee benefits expense	13.32	33.37	12.84	26.16	64.20	139
	Depreciation and Amortisation expense	0.33	0.39	0.33	0.66	0.63	1
	Other Expenses	21.29	55.23	18.63	39.92	128.16	200
	Total Expenses	34.94	94.89	31.99	66.93	206.14	364.
V	Profit/(Loss) from before Exceptional Items and						3011
	tax (I-IV)	(31.30)	(53.99)	(27.15)	(58.45)	(123.02)	(205.2
VI	Exceptional Items	-	-	-	-	-	1203.1
VII	Profit/(Loss) before tax (V-VI)	(31.30)	(53.99)	(27.15)	(58.45)	(123.02)	(205.2
VIII	Tax Expense:	-	-	-		-	1203.
	Current Tax		-				
	Deferred Tax	(1.04)			(1.04)		(7.1
X	Profit/ (Loss) for the period from Continuing						(/
	operations (VII-VIII)	(30.26)	(53.99)	(27.15)	(57.41)	(123.02)	(198.:
X	Profit/ (Loss) from discontinuing operations				-	(223.02)	(150
ΚI	Tax Expense of discontinuing operations					-	-
XII		-	•	-	-	14	_
AII	Profit/ (Loss) for the period from discontinuing						
	operations after tax (X-XI)	-	-	-			_
XIII	Profit/ (Loss) for the period (IX+XII)	(30.26)	(53.99)	(27.15)	(57.41)	(123.02)	(198.1
XIV	Other Comprehensive Income  A) (i) Items that will not be reclassified to profit or loss					(223.02)	(150.1
	(ii) Income Tax related to items that will not be reclassified to profit or loss B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss						
XV		1.42		-	1.42	-	1.8
AV	Total Comprehensive Income for the period						
	(XIII+XIV) (Comprising Profit (loss) and Other	100,000,000	5-000000		200000000000000000000000000000000000000		
	Comprehensive Income for the Period)	(28.84)	(53.99)	(27.15)	(55.99)	(123.02)	(196.3
XVI	Comprehensive Income attributable to Non						
	Controlling Interest	(0.29)	-	-	(0.29)		(4.4
XVII	Comprehensive Income attributable to Owners of				,		14.4
	the company	(28.55)	(53.99)	(27.15)	(55.70)	(400 00)	
XVIII	Earnings Per Equity Share (For Continuing	(20.55)	(33.33)	(27.15)	(55.70)	(123.02)	(191.8
~*****	Operations) (Face Value INR 10/- each)						
	1) Basic	(0.19)		(0.19)	(0.04)	(0.83)	(1.3
	2) Diluted	(0.19)	(0.36)	(0.19)	(0.04)	(0.83)	(1.3
αX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)  1) Basic	19					
	2) Diluted	11 7					
~		-	•	-			
ΟX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/-						
	each) 1)						
	Basic	(0.19)	(0.36)	(0.19)	(0.38)	(0.02)	10.0
	2) Diluted				(0.38)	(0.83)	(1.3
OVI.		(0.19)	(0.36)	(0.19)	(0.38)	(0.83)	(1.3
	Paid Up Equity Share Capital (Face Value of INR	1 490 97	1400.07	1 400 07	4 400 07		
	10/- per share)	1,480.87	1480.87	1,480.87	1,480.87	1480.87	1480

### Notes:

- The above unaudited consolidated financial results for the quarter and half year ended 30 September 2020 have been subject to a limited review by the statutory auditors, and reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Friday 13 November 2020.
- The unaudited consolidated financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of Companies Act, 2013 and other accounting principles generally accepted in India and in terms Regulation 33 of SEBI (LODR) Regulations, 2015.
- The format for the consolidated unaudited quarterly and half year ended results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed.
- 4 The EPS for quarters has not been annualized.
- The company continues to consider the impact of COVID-19 pandemic in assessing the improvement of business and recoverability of receivables. For this purpose, the company considered internal and external sources of information up to the date of approval of these financial results.

  The Company based on its judgements, estimates and assumptions expects to recover the carrying amount of receivables and other assets.

  The impact of the global health pandemic may be different from that estimated as at the date of approval of financials results and the Company will continue to closely monitor any material changes to future economic conditions.

  Entity operated its hospital in the month of June'2020 only for seven days after relaxation of lockdown rules but later the same was shut down and not stared till date. Hence there is no revenue in second quarter i.e. July 2020 September 2020.
- The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.

  The unaudited financial results for the quarter and half year ended 30 September, 2020 are also available on the website of the Company www.drhlsl.com
- 9 The Provious quarters / year's figures have been regrouped /rearranged wherever personal for the automorphism

The Previous quarters/ year's figures have been regrouped/rearranged wherever necessary, for the purpose of comparison.

Place: Hyderabad Date: 13/11/2020 FOR DR HABEEBULLAH LIFE SCIENCES LIMITED

K. Krishnam Raju

Executive Chairman (DIN 00874650)

Particulars		Life Sciences Limited ent of Assets and Liabilities	
ASSETS 1 Non Current Assets 2 Property Plant and Equipment 5 Capital Work in Progress 6 Codwill 6 Codwill 6 Codwill 7 Codwill 7 Codwill 8 Codwill 8 Codwill 8 Codwill 8 Codwill 8 Codwill 9 Codwill		Half Year Ended	(Amount in Lakh
Non-Current Assets		9/30/2020	
a) Property, Plant and Equipment b Capital Work In Progress c Investment Property d Goodwill e) Other Intangible Assets under development f Intangible Assets under development g Biological assets other than bearer plants h Financial Assets: ii Trade Receivables iii Loans vi Others c Loans vi Others d Loans vi Other Intancial Assets vi Loans vi			,
Display   Disp	a Property, Plant and Equipment	6.0	25
Content   Cont	Capital Work In Progress	0.5	13.1
G   Goodwill   Content	C Investment Property		-
International Assets under development   1,923,06   1,89	d Goodwill		-
1,80   1,80	e Other Intangible Assets	_	-
1.99   Financial Assets   1.99   1.	Riological assets under development	1,923.0	6
il Investments ii Trade Receivables iii Laam volume to Others v Loans	h Financial Assets other than bearer plants	-	1,899.20
II Trade Receivables   0.75		-	-
		0.7	5
iv Others v Loans v Deferred Tax Assets (net) j Other Non Current Assets Total Non Current Assets Total Non Current Assets  2,182.18 2,163.  2 Current Assets a Inventories b Financial Assets i Investments i Tade Receivables i Tade Receivables i Total Receivables i Total Receivables i Total Current Assets f Current Tax Assets (net) t Cother financial assets c Current Tax Assets (net) f Other Financial Assets Total Current Assets Total Current Assets Total Assets  EQUITY AND LIABILITIES Equity Equity Share Capital Other Equity Share Warrants Shar	iii Loans	-	0.75
Vi Others   Deferred Tax Assets (net)   Jother Non Current Assets   47,14   465     Total Non Current Assets   2,182,18   2,163, 2,163, 2,182,18     Current Assets   2,182,18   2,163, 2,163, 2,182,18     Current Assets   12,92   13, 13, 13, 14, 14, 15, 14, 14, 15, 14, 14, 15, 14, 14, 15, 14, 14, 15, 14, 14, 15, 14, 14, 14, 15, 14, 14, 14, 15, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14	iv Others	1000	
Others	I I	204.28	204.28
JOHR YON CUrrent Assets		-	-
Jother Non Current Assets	i Deferred Tax Assets (net)	47.1	.   -
2   2   2   2   163   2	JOther Non Current Assets	47.14	46.10
Current Assets   12.92   13   13   15   15   15   15   15   15	Total Non Current Assets	2 182 19	-
al Investments i Irrade Receivables Irrade	2	2,102.10	2,163.57
b Financial Assets i Investments i Investments ii Trade Receivables iii Cash and Cash Equivalents iii Total Receivables iii Cash and Cash Equivalents iii Total Receivables iii Cash and Cash Equivalents iii Cash and Cash Equivalents iii Cash and Cash Equivalents iii Other financial assets iii Other financial assets iii Cash and Cash Equivalents iii Other Financial assets iii Other financial Sasets iii Other Financial Sasets iii Other Financial Liabilities Financial Liabilities India Financial F			
i Investments ii Trade Receivables ii Trade Receiva		12.92	12.14
ii Trade Receivables ii Cash and Cash Equivalents v Bank balances other than above v Loans v L		-	13.11
iii Cash and Cash Equivalents		-	
Value   Valu	ii Cash and Cash Equivalents	214.26	217.51
Clarent Tax Assets (net)	v Bank balances other than above	1.41	2.94
Current Tax Assets (net) 30.75 24.  Total Current Assets 306.21 305.25  Total Current Assets 5659.55 657.6  Total Assets 2,841.73 2,821.2  EQUITY AND LIABILITIES Equity Equity Share Capital Other Equity 1,480.87 1,480.8  Other Equity 5hare Capital 1,480.87 1,480.8  Total Equity 5hare Capital 1,480.87 1,480.8  Share Warrants (358.26) (302.55 400.26 400.55 400.26 400.55 100.26 10	v Loans	-	-
Other Current Assets   306.21   305.55   657.65   659.55   659.55   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.55   659.65   659.65   659.55   659.6			94.00
Total Current Assets	Current Tax Assets (net)	30.75	24.10
Company   Comp		206.21	-
Total Assets	Total Current Assets		305.97
EQUITY AND LIABILITIES  Equity Equity Share Capital Other Equity Share Warrants Reserves and Surplus Non-Controlling Interests Total Equity 1,522.87  Liabilities Non Current Liabilities Financial Liabilities Borrowings Other Financial Liabilities Provisions Deferred Tax Liabilities (net) Other Non Current Liabilities Financial Liabilities  Deferred Tax Liabilities Indicate Surrent Survey Indicate Survey In	Total Assets		
Equity   Equity Share Capital   1,480.87   1,480.88   1,480.87   1,480.88   1,480.87   1,480.88	FOURTY AND LINE	2,041.73	2,821.22
Equity Share Capital	Equity AND LIABILITIES		
Other Equity   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,578.86   1,480.87   1,480			
Share Warrants Reserves and Surplus Non-Controlling Interests Total Equity  Liabilities Non Current Liabilities Financial Liabilities Foroxions Other Financial Liabilities Provisions Deferred Tax Liabilities Fotal Non Current Liabilities Financial Liabilities  14.48 14.50 Current Liabilities  14.48 14.50 Current Liabilities 14.48 14.50 Current Liabilities 15.50 Current Liabilities 16.50 Current Liabilities 17.50 Current Liabilities 18.50 Current Liabilitie		1,480.87	1 480 87
Reserves and Surplus Non-Controlling Interests Total Equity  Liabilities Non Current Liabilities Financial Liabilities Borrowings Trade Payables Other Financial Liabilities Other Non Current Liabilities Other Non Current Liabilities Total Non Current Liabilities The Financial Liabili		-	1,400.67
Non-Controlling Interests			
Total Equity	Non-Controlling Interests		(302.56)
Liabilities Non Current Liabilities Financial Liabilities Borrowings Trade Payables Other Financial Liabilities Provisions Deferred Tax Liabilities (net) Other Non Current Liabilities Fiotal Non Current Liabilities Current Liabilities Financial Liabilities Financi	Total Equity		400.55
Non Current Liabilities Financial Liabilities Borrowings Trade Payables Other Financial Liabilities Provisions Deferred Tax Liabilities Other Non Current Liabilities Total Non Current Liabilities Total Non Current Liabilities Total Non Current Liabilities The Liabilities Transcial Liabilities Transcial Liabilities Transcial Liabilities The Financial Liab		1,522.87	1,578.86
Financial Liabilities Borrowings Trade Payables Other Financial Liabilities Provisions Deferred Tax Liabilities   14,48   14,50   Other Non Current Liabilities   -			
Borrowings Trade Payables Other Financial Liabilities Provisions Deferred Tax Liabilities (net) Other Non Current Liabilities Fotal Non Current Liabilities Total Non Current Liabilities Total Liabilities The Financial Liabilities Trade Payables T			1
Trade Payables Other Financial Liabilities Provisions Deferred Tax Liabilities (net) Other Non Current Liabilities Fotal Non Current Liabilities Total Non Current Liabilities The Liabilities Trade Payables Trade Paya			
Other Financial Liabilities Provisions Deferred Tax Liabilities (net) Other Non Current Liabilities Fotal Non Current Liabilities  Idvargent Liabilities Inancial Liabilities Inancial Liabilities Inancial Liabilities Interpret Liabilities Inte	3	1	
Provisions Deferred Tax Liabilities (net) Deferred Tax Liabilities Defe		- 1	
Deferred Tax Liabilities (net) Deferred Tax Liabilities 14.50 Deferred Tax Liabilities 15. Deferred Tax Liabilities 15. Deferred Non Current Liabilities 15. Deferred Tax Liabilities 15. Defe		-	
Total Non Current Liabilities  Total Liabilities  Total Liabilities  Total Current Liabilities  Total Non Current Liabilitie		14.48	14.50
Total Non Current Liabilities  Lurrent Liabilities inancial Liabilities inancial Liabilities orrowings rade Payables ther Financial Liabilities ther Current Liabilities rovisions urrent Tax Liabilities (net) otal Current Liabilities  1,304.38  1,227.86		-	
inancial Liabilities inancial Liabilities orrowings rade Payables other Financial Liabilities other Current Liabilities rovisions urrent Tax Liabilities (net) otal Current Liabilities  1,304.38		-	
inancial Liabilities orrowings rade Payables ther Financial Liabilities ther Current Liabilities ovisions urrent Tax Liabilities (net) otal Current Liabilities  1,304.38  858.40 34.93 30.50 370.91 2.83 2.43		14.48	14.50
orrowings rade Payables ther Financial Liabilities ther Current Liabilities rovisions urrent Tax Liabilities (net) otal Current Liabilities  895.71 858.40 34.93 30.50 370.91 2.83 2.83 2.43	Current Liabilities		
grade Payables       895.71       858.40         ather Financial Liabilities       34.93       30.50         ther Current Liabilities       370.91       336.53         arrent Tax Liabilities (net)       2.83       2.43         atal Current Liabilities       1,304.38       1,227.86	inancial Liabilities		
ther Financial Liabilities ther Current Liabilities rovisions urrent Tax Liabilities (net)  otal Current Liabilities  1,304.38  30.50  370.91  2.83  2.43	3	905.71	
ther Current Liabilities ovisions urrent Tax Liabilities (net) otal Current Liabilities  1,304.38  370.91  2.83  2.43  1,227.86			
ovisions     370.91     336.53       urrent Tax Liabilities (net)     2.83     2.43       otal Current Liabilities     1,304.38     1,227.86		34.93	30.50
2.83 2.43 2.43 2.43 2.43 2.43 2.43 2.43 2.4		370.91	220.55
tal Current Liabilities (net)  1,304.38 1,227.86			
1,304.38 1,227.86			2.43
2,227.00	tal Current Liabilities	1,304.38	1 227 86
Tal Equity and Liabilities	tal Equity and Liabilities		4,227.00
2,841.73 2,821.22			1155

FOR DR HABEEBULLAH LIFE SCHENCES LIMIT

Place: Hyderabad Date: 13/11/2020

K. Krishnam Raju Executive Chairman (DIN 00874650)

### DR HABEEBULLAH LIFE SCIENCES LIMITED CONSOLIDATED STATEMENT OF CASH FLOWS

(Amount in Lakhs.)

	(Amount in Lakhs.)			
PARTICULARS	Half Year ended	Half Year ended		
	September 30, 2020	September 30, 2019		
A. CASH FLOW FROM OPERATING ACTIVITIES :				
Net profit before tax	(57.02)	/122.0		
Adjustment for:	(57.03)	(123.0		
Depreciation and Amortisation	0.55	0.5		
Interest Expenses	0.66	0.6		
Interest Earned		15.5		
Cash Flows from Operations before changes in assets and liabilities	(56.37)	(5.6-		
Total YOUR CORE STOCK STOCK STOCK SECTION SECT	(50.57)	(120.0.		
Movements in Working Capital::				
(Increase)/ Decrease in trade receivables	3.26	0.53		
(Increase) / Decrease in Short term Loans and Advances	-	-		
(Increase)/Decrease in other financial assets Assets	(6.65)	-		
(Increase)/Decrease in other Current Assets	(0.24)	(114.75		
(Increase) / Decrease in Inventories	0.19	0.11		
Increase / (Decrease) in Trade Payables	4.43	145.53		
Increase/(Decrease) in Other current liabilities	34.38	(7.01		
Increase/(Decrease) in Current Provisions	0.40	(0.76		
Change in Working Capital	35.78	23.65		
Changes in non current assets and liabilities				
Decrease/(Increase) in loans & advances		/1 77		
(Decrease)/Increase in Long Term Provisions	(0.01)	(1.73		
Changes in non current assets and liabilities	(0.01)	0.76		
	(5.52)	(0.57		
Cash Generated From Operations	(20.61)	(105.35		
Less: Taxes paid	-	-		
Net Cash from operating activities(A)	(20.61)	(105.35		
	(-0.02)	(203.33		
B. CASH FLOW FROM INVESTING ACTIVITIES				
(Increase) / Decrease in Fixed assets and Capital Work In progress	(18.23)	(56.78		
Bank Balances not considered as Cash and Cash equivalents		-		
Investment in equity Shares		-		
Interest earned		5.64		
Net cash used in Investing activities (B)	(18.23)	(51.14		
C.CASH FLOW FROM FINANCING ACTIVITIES				
Increase / (Decrease) in Share Capital		150.00		
Increase / (Decrease) in Borrowings	37.31			
Interest paid	37.31	8.10		
Net cash Flow from Financing Activities ( C )	37.31	158.10		
	37.32	130.10		
let Increase/(Decrease) in cash & cash equivalents [A+B+C]	(1.53)	1.61		
ASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	2.94	1.50		
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	1.41	3.11		

For and on behalf of the Board


for DR HABEEBULLAH LIFE SCIENCES LIMITED TEST

Place: Hyderabad

Date: 13/11/2020

(K.Krishnam Raju) Whole-time Director & Chairman

DIN: 00874650





Independent Auditor's Review Report on unaudited quarterly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

То

The Board of Directors

Dr Habeebullah Life Sciences Limited

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of **Dr Habeebullah Life Sciences Limited** ('the Company') for the quarter ended September, 2020 and the year to-date results for the period April 01, 2020 to September 30,2020 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. We draw attention to Note. 5 to the financial results which states that the management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the period ended September 30, 2020.



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W

ananthak by Digitally signed by ananthakrishnan govindan Date: 2020.11.13 16:55:15 +05'30'



Ananthkrishnan Govindan

Partner

Membership No: 205226

UDIN: 20205226AAAAJB1064

Place: Hyderabad

Date: November 13,2020



Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date financial results of the Dr Habeebullah Life Sciences Limited and its subsidiary pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

## The Board of Directors Dr Habeebullah Life Sciences Limited

- 1. We have reviewed the accompanying statement of consolidated unaudited financial results of **Dr Habeebullah Life Sciences Limited** ('the Holding Company'), its subsidiary, (the Holding Company and its subsidiary together referred to as the 'Group') for the quarter ended September 30, 2020 and the year to-date results for the period from April 01, 2020 to September 30, 2020 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
- 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entity:

Sr. No	Name of the Company	Relationship with the Holding Company
1	Krisani Bio Sciences Private Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has



come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

- 6. We draw attention to Note. 5 to the financial results which states that the management has made an assessment of the impact of COVID-19 on the Company's operations, financial performance and position as at and for the period ended September 30, 2020.
- 7. The consolidated unaudited financial results include the interim financial information of subsidiary (mentioned in paragraph 4 above) which have not been reviewed or audited by their auditors, whose financial information reflect Group's share of total assets of Rs. 1,657 lakhs (before consolidation adjustments) as at September 30, 2020 and Group's share of total revenue is Nil (before consolidation adjustments) and Group's share of total net loss after tax of Rs. 0.60 lakhs (before consolidation adjustments) for the quarter ended September 30,2020 and for the period from April 01, 2020 to September 30, 2020, respectively, and Group's share of cash flows (net) of Rs. 0.62 lakhs (before consolidation adjustments) for the period from April 01,2020 to September 30,2020 as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also include the Group's share of net loss after tax of Rs. 0.31 lakhs for the half year ended September 30, 2020. According to information and explanation given to us by the management, this interim financial information is not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the management.

#### For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W

ananthakrish Digitally signed by nan govindan Date: 2020.11.13 1655:58

Ananthkrishnan G

Partner

Membership No: 205226

UDIN: 20205226AAAAJC5632

Place: Hyderabad

Date: November 13,2020